Recent News

• 03.24.2025 - Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
• 03.10.2025 - Leerink's Global Healthcare Conference 2025
• 03.03.2025 - Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
• 03.03.2025 - Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
• 01.23.2025 - Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
• 12.16.2024 - Larimar Mid-December 2024 Program Update
• 12.16.2024 - Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia
• 11.18.2024 - Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Recent Filings

• 02.04.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.27.2025 - 8-K Current report
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.10.2025 - 8-K Current report
• 01.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.16.2024 - EX-99.1 EX-99.1
• 12.16.2024 - 8-K Current report